https://european-biotechnology.com/wp-content/uploads/2024/04/TargetED_Biopharmaceuticals-scaled.jpeg16302560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-22 16:34:312024-04-04 16:47:36TargED Biopharmaceuticals BV raises €39m in Series A financing
The cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
https://european-biotechnology.com/wp-content/uploads/2024/04/Lonza.jpeg571700Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-21 17:03:002024-04-04 16:47:44Moderna wants to extent its European footprint
InDex Pharmaceuticals needs a new COO. After ten years as Chief Operating Officer, Pernilla Sandwall will leave the Stockolm-based company at the end of April.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Pernilla_Sandwall_kl.jpg489435Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-02-17 11:24:002024-07-16 17:58:29COO will leave InDex Pharmaceuticals
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Newton_Capital.jpeg10002267Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-15 08:26:202024-04-04 16:47:46Newton Biocapital launches new NBC III fund
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_piggy-bank-g0355543d7_1280-pixabay.jpeg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-13 17:11:002024-04-04 16:47:47New funds to boost European life sciences
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
ECBF oversubscribed closing at €300m
Latest NewsThe European Circular Bioeconomy Fund has announced its final closing at €300m, €50m above its target.
TargED Biopharmaceuticals BV raises €39m in Series A financing
Latest NewsTargED Biopharmaceuticals will use €39m from a Series A financing to bring its thrombolytic treatment to patients.
Finnish VTT spin-out Onego Bio Ltd raises €10m
Latest NewsThe cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
Moderna wants to extent its European footprint
Latest NewsThe former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
COO will leave InDex Pharmaceuticals
AppointmentsInDex Pharmaceuticals needs a new COO. After ten years as Chief Operating Officer, Pernilla Sandwall will leave the Stockolm-based company at the end of April.
Centauri Therapeutics starting with £24m financing
Latest NewsAntimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics in US$1.7bn deal with MSD
Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital launches new NBC III fund
Latest NewsNewton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
New funds to boost European life sciences
Latest NewsEuropean investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
Latest NewsAiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.